A Phase II Prospective, Single Blinded, Randomized Trial of Hemopatch Compared to Standard Techniques to Achieve Air Leak Control After Complex Thoracic Surgical Procedures (Hemopatch)
A Phase II Prospective, Single Blinded, Randomized Trial of Hemopatch Compared to Standard Techniques to Achieve Air Leak Control After Complex Thoracic Surgical Procedures on High Risk Population for Prolonged Air Leak (> 5 Days - PAL).
Sponsor: Baxter Healthcare Corporation
Listed as NCT02364791, this PHASE2 trial focuses on Post-operative Thoracic Air Leak and Thoracic Surgery Lung and remains ongoing. Sponsored by Baxter Healthcare Corporation, it has been updated 9 times since 2015, reflecting limited change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.
Status Flow
Change History
9 versions recorded-
Apr 2025 — Present [monthly]
Unknown PHASE2
Status: Active Not Recruiting → Unknown
-
Sep 2024 — Apr 2025 [monthly]
Active Not Recruiting PHASE2
-
Jul 2024 — Sep 2024 [monthly]
Active Not Recruiting PHASE2
-
Apr 2023 — Jul 2024 [monthly]
Active Not Recruiting PHASE2
-
Apr 2021 — Apr 2023 [monthly]
Active Not Recruiting PHASE2
Status: Unknown Status → Active Not Recruiting
▶ Show 4 earlier versions
-
Jan 2021 — Apr 2021 [monthly]
Unknown Status PHASE2
-
Apr 2019 — Jan 2021 [monthly]
Unknown Status PHASE2
Status: Recruiting → Unknown Status
-
Jun 2018 — Apr 2019 [monthly]
Recruiting PHASE2
-
Jan 2017 — Jun 2018 [monthly]
Recruiting PHASE2
First recorded
Feb 2015
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Baxter Healthcare Corporation
- European Institute of Oncology
- Fondazione IRCCS Istituto Nazionale dei Tumori, Milano
- Istituto Clinico Humanitas
- National Cancer Institute, Naples
- Regina Elena Cancer Institute
For direct contact, visit the study record on ClinicalTrials.gov .